The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia

Hongming Zhu, Jiong Hu, Li Chen, Wei Zhou, Xiaoyang Li, Lining Wang, Xia Zhao, Yunxiang Zhang, Huijin Zhao, Aihua Wang, Yú Chen, Huiping Sun, Qiusheng Chen, Weili Zhao, Jian‐Qing Mi, Zhixiang Shen, Zhenyi Wang, Chen Zhu, Sai‐Juan Chen, Junmin LiBlood 2016 · DOI · OpenAlex

Abstract

To the editor: Arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) have demonstrated notable success in the treatment of acute promyelocytic leukemia (APL).[1][1][⇓][2]-[3][3] However, few studies have reported the adverse effects (AEs), long-term toxicity, and secondary carcinogenesis of
BibTeX
@inproceedings{zhu2016year,
  author = {Hongming Zhu and Jiong Hu and Li Chen and Wei Zhou and Xiaoyang Li and Lining Wang and Xia Zhao and Yunxiang Zhang and Huijin Zhao and Aihua Wang and Yú Chen and Huiping Sun and Qiusheng Chen and Yù Chen and Weili Zhao and Jian‐Qing Mi and Zhixiang Shen and Zhenyi Wang and Chen Zhu and Sai‐Juan Chen and Junmin Li},
  title = {{The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia}},
  booktitle = {Blood},
  year = {2016},
  doi = {10.1182/blood-2016-02-699439},
}

Loading related content...

Figure